Citations

Clear

1053 citation(s) found for "Andre, F".

Bioinnovation Enterprise: An engine driving breakthrough therapies
Waldman, Scott A. , Terzic, André , Waldman, Scott A

Mayo Clinic

Clinical Pharmacology & Therapeutics | December 22, 2015 | Volume: 99 | Issue: 1 | Pages: 8-13

10.1002/cpt.272 | PMID 26785918 Get It

Biological advances have radically expanded our insights into the underpinnings of health and disease. New knowledge has formed the substrate for translation—expedited in turn by the biotechnology and pharmaceutical industry into novel therapeutic solutions impacting the management of patients and populations. Indeed, this Bioinnovation Enterprise has become the dominant growth sector in drug development and the engine driving the translation of breakthrough therapies worldwide. This annual Therapeutic Innovations issue highlights recent exceptional advances by the Bioinnovation Enterprise in translating molecular insights in pathobiology into transformative therapies.
Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) Trial Design
Sherman, Warren, Povsic, Thomas J. , Henry, Timothy D. , Metra, Marco , Filippatos, Gerasimos , Hajjar, Roger J. , Behfar, Atta , Homsy, Christian, Wijns, William , Tendera, Michał , Bartúnek, Jozef , Davison, Beth A. , Gersh, Bernard J. , Cotter, Gad , Terzic, André , Behfar, Atta , Metra, Marco , Wijns, William

Mayo Clinic

European Journal of Heart Failure | December 14, 2015 | Volume: 18 | Issue: 2 | Pages: 160-168

10.1002/ejhf.434 | PMID 26662998 Get It

Abstract Aims Cardiopoiesis is a conditioning programme that aims to upgrade the cardioregenerative aptitude of patient-derived stem cells through lineage specification. Cardiopoietic stem cells tested initially for feasibility and safety exhibited signs of clinical benefit in patients with ischaemic heart failure (HF) warranting definitive evaluation. Accordingly, CHART-1 is designed as a large randomized, sham-controlled multicentre study aimed to validate cardiopoietic stem cell therapy. Methods Patients (n = 240) with chronic HF secondary to ischaemic heart disease, reduced LVEF (<35%), and at high risk for recurrent HF-related events, despite optimal medical therapy, will be randomized 1:1 to receive 600 × 106 bone marrow-derived and lineage-directed autologous cardiopoietic stem cells administered via a retention-enhanced intramyocardial injection catheter or a sham procedure. The primary efficacy endpoint is a hierarchical composite of mortality, worsening HF, Minnesota Living with Heart Failure Questionnaire score, 6 min walk test, LV end-systolic volume, and LVEF at 9 months. The secondary efficacy endpoint is the time to cardiovascular death or worsening HF at 12 months. Safety endpoints include mortality, readmissions, aborted sudden deaths, and serious adverse events at 12 and 24 months. Conclusion The CHART-1 clinical trial is powered to examine the therapeutic impact of lineage-directed stem cells as a strategy to achieve cardiac regeneration in HF populations. On completion, CHART-1 will offer a definitive evaluation of the efficacy and safety of cardiopoietic stem cells in the treatment of chronic ischaemic HF. Trial registration: NCT01768702
Genome-Wide Studies Reveal that H3K4me3 Modification in Bivalent Genes Is Dynamically Regulated during the Pluripotent Cell Cycle and Stabilized upon Differentiation
Grandy, Rodrigo A. , Whitfield, Troy W. , Wu, Hai , VanOudenhove, Jennifer , Zaidi, Sayyed K. , Montecino, Martı́n , Lian, Jane B. , Wijnen, André J. van , Stein, Janet L. , Stein, Gary S., van Wijnen, Andre J, Fitzgerald, Mark P. , van Wijnen, Andre J

Mayo Clinic

Molecular and Cellular Biology | December 8, 2015 | Volume: 36 | Issue: 4 | Pages: 615-627

10.1128/mcb.00877-15 | PMID 26644406 Get It

Regenerative Medicine Build-Out
Pfenning, Michael, Harper, C. Michel , Pfenning, Michael A, Terzic, André , Gores, Gregory J.

Mayo Clinic

Stem Cells Translational Medicine | November 5, 2015 | Volume: 4 | Issue: 12 | Pages: 1373-1379

10.5966/sctm.2015-0275 | PMID 26537392 Get It

Abstract Summary Regenerative technologies strive to boost innate repair processes and restitute normative impact. Deployment of regenerative principles into practice is poised to usher in a new era in health care, driving radical innovation in patient management to address the needs of an aging population challenged by escalating chronic diseases. There is urgency to design, execute, and validate viable paradigms for translating and implementing the science of regenerative medicine into tangible health benefits that provide value to stakeholders. A regenerative medicine model of care would entail scalable production and standardized application of clinical grade biotherapies supported by comprehensive supply chain capabilities that integrate sourcing and manufacturing with care delivery. Mayo Clinic has rolled out a blueprint for discovery, translation, and application of regenerative medicine therapies for accelerated adoption into the standard of care. To establish regenerative medical and surgical service lines, the Mayo Clinic model incorporates patient access, enabling platforms and delivery. Access is coordinated through a designated portal, the Regenerative Medicine Consult Service, serving to facilitate patient/provider education, procurement of biomaterials, referral to specialty services, and/or regenerative interventions, often in clinical trials. Platforms include the Regenerative Medicine Biotrust and Good Manufacturing Practice facilities for manufacture of clinical grade products for cell-based, acellular, and/or biomaterial applications. Care delivery leverages dedicated interventional suites for provision of regenerative services. Performance is tracked using a scorecard system to inform decision making. The Mayo Clinic roadmap exemplifies an integrated organization in the discovery, development, and delivery of regenerative medicine within a growing community of practice at the core of modern health care. Significance Regenerative medicine is at the vanguard of health care poised to offer solutions for many of today's incurable diseases. Accordingly, there is a pressing need to develop, deploy, and demonstrate a viable framework for rollout of a regenerative medicine model of care. Translation of regenerative medicine principles into practice is feasible, yet clinical validity and utility must be established to ensure approval and adoption. Standardized and scaled-up regenerative products and services across medical and surgical specialties must in turn achieve a value-added proposition, advancing intended outcome beyond current management strategies.
Evidence for Direct Physical Association between a K+Channel (Kir6.2) and an ATP-Binding Cassette Protein (SUR1) Which Affects Cellular Distribution and Kinetic Behavior of an ATP-Sensitive K+ Channel
Alekseev, Alexey E., Krapivinsky, Grigory, Carrasco, Antonio J., Clapham, David E. , Lorenz, Eva , Carrasco, Antonio J., Terzic, André

Mayo Clinic

Molecular and Cellular Biology | October 10, 2015 | Volume: 18 | Issue: 3 | Pages: 1652-1659

10.1128/mcb.18.3.1652 | PMID 9488482 Get It

Multi‐disciplinary antimicrobial strategies for improving orthopaedic implants to prevent prosthetic joint infections in hip and knee
Getzlaf, Matthew A., Lewallen, Eric A. , Kremers, Hilal Maradit , Jones, Dakota L. , Bonin, Carolina A. , Dudakovic, Amel , Thaler, Roman , Cohen, Robert C., Lewallen, David G. , Wijnen, André J. van , Kremers, Hilal M, van Wijnen, Andre J, van Wijnen, Andre J , Maradit Kremers, Hilal

Mayo Clinic

Journal of Orthopaedic Research | October 9, 2015 | Volume: 34 | Issue: 2 | Pages: 177-186

10.1002/jor.23068 | PMID 26449208 Get It

ABSTRACTLike any foreign object, orthopaedic implants are susceptible to infection when introduced into the human body. Without additional preventative measures, the absolute number of annual prosthetic joint infections will continue to rise, and may exceed the capacity of health care systems in the near future. Bacteria are difficult to eradicate from synovial joints due to their exceptionally diverse taxonomy, complex mechanistic attachment capabilities, and tendency to evolve antibiotic resistance. When a primary orthopaedic implant fails from prosthetic joint infection, surgeons are generally challenged by limited options for intervention. In this review, we highlight the etiology and taxonomic groupings of bacteria known to cause prosthetic joint infections, and examine their key mechanisms of attachment. We propose that antimicrobial strategies should focus on the most harmful bacteria taxa within the context of occurrence, taxonomic diversity, adhesion mechanisms, and implant design. Patient‐specific identification of organisms that cause prosthetic joint infections will permit assessment of their biological vulnerabilities. The latter can be targeted using a range of antimicrobial techniques that exploit different colonization mechanisms including implant surface attachment, biofilm formation, and/or hematogenous recruitment. We anticipate that customized strategies for each patient, joint, and prosthetic component will be most effective at reducing prosthetic joint infections, including those caused by antibiotic‐resistant and polymicrobial bacteria. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:177–186, 2016.
Induced Pluripotent Stem Cells for Cardiovascular Disease: From Product-Focused Disease Modeling to Process-Focused Disease Discovery
Campbell, Katherine , Campbell, Katherine A, Terzic, André , Nelson, Timothy J.

Mayo Clinic

Regenerative Medicine | October 6, 2015 | Volume: 10 | Issue: 6 | Pages: 773-783

10.2217/rme.15.41 | PMID 26439809 Get It

Intrarenal Delivery of Mesenchymal Stem Cells and Endothelial Progenitor Cells Attenuates Hypertensive Cardiomyopathy in Experimental Renovascular Hypertension
Eirin, Alfonso , Zhu, Xiang-Yang, Ebrahimi, Behzad , Krier, James D., Riester, Scott M. , Wijnen, André J. van , Lerman, Lilach O. , Lerman, Amir , van Wijnen, Andre J , Eirin, Alfonso

Mayo Clinic

Cell Transplantation | September 29, 2015 | Volume: 24 | Issue: 10 | Pages: 2041-2053

10.3727/096368914x685582 | PMID 25420012 Get It

Renovascular hypertension (RVH) leads to left ventricular (LV) hypertrophy and diastolic dysfunction, associated with increased cardiovascular mortality. Intrarenal delivery of endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) improves kidney function in porcine RVH, and the potent anti-inflammatory properties of MSCs may serve to blunt inflammatory mediators in the cardiorenal axis. However, their relative efficacy in attenuating cardiac injury and dysfunction remains unknown. This study tested the hypothesis that the car-dioprotective effect of EPCs and MSCs delivered into the stenotic kidney in experimental RVH are comparable. Pigs ( n = 7 per group) were studied after 10 weeks of RVH or control untreated or treated with a single intrarenal infusion of autologous EPCs or MSCs 4 weeks earlier. Cardiac and renal function (fast CT) and stenotic kidney release of inflammatory mediators (ELISA) were assessed in vivo, and myocardial inflammation, remodeling, and fibrosis ex vivo. After 10 weeks of RVH, blood pressure was not altered in cell-treated groups, yet stenotic kidney glomerular filtration rate (GFR), blunted in RVH, improved in RVH + EPC, and normalized in RVH + MSCs. Stenotic kidney release of monocyte chemoattractant protein (MCP)-1 and its myocardial expression were elevated in RVH + EPC, but normalized only in RVH + MSC pigs. RVH-induced LV hypertrophy was normalized in both EPC- and MSC-treated pigs, while diastolic function (E/A ratio) was restored to normal levels exclusively in RVH + MSCs. RVH-induced myocardial fibrosis and collagen deposition decreased in RVH + EPCs but further decreased in RVH + MSC-treated pigs. Intrarenal delivery of EPCs or MSCs attenuates RVH-induced myocardial injury, yet MSCs restore diastolic function more effectively than EPCs, possibly by greater improvement in renal function or reduction of MCP-1 release from the stenotic kidney. These observations suggest a therapeutic potential for EPCs and MSCs in preserving the myocardium in chronic experimental RVH.
Ligament Tissue Engineering Using a Novel Porous Polycaprolactone Fumarate Scaffold and Adipose Tissue-Derived Mesenchymal Stem Cells Grown in Platelet Lysate
Wagner, Eric R. , Bravo, Dalibel , Dadsetan, Mahrokh, Riester, Scott M. , Chase, Steven C. , Dietz, Allan B. , Wijnen, André J. van , Yaszemski, Michael J. , Chase, Steven, van Wijnen, Andre J, Westendorf, Jennifer J. , Kakar, Sanjeev , van Wijnen, Andre J , Dietz, Allan B , Wagner, Eric R

Mayo Clinic

Tissue Engineering Part A | September 28, 2015 | Volume: 21 | Issue: 21-22 | Pages: 2703-2713

10.1089/ten.tea.2015.0183 | PMID 26413793 Get It

Histone Deacetylases in Bone Development and Skeletal Disorders
Bradley, Elizabeth W. , Carpio, Lomeli R., Wijnen, André J. van , McGee‐Lawrence, Meghan E. , Westendorf, Jennifer J., Shull, Lomeli C. , van Wijnen, Andre J, Westendorf, Jennifer J. , van Wijnen, Andre J , Bradley, Elizabeth W , McGee-Lawrence, Meghan E

Mayo Clinic

Physiological Reviews | September 17, 2015 | Volume: 95 | Issue: 4 | Pages: 1359-1381

10.1152/physrev.00004.2015 | PMID 26378079 Get It

Histone deacetylases (Hdacs) are conserved enzymes that remove acetyl groups from lysine side chains in histones and other proteins. Eleven of the 18 Hdacs encoded by the human and mouse genomes depend on Zn2+for enzymatic activity, while the other 7, the sirtuins (Sirts), require NAD2+. Collectively, Hdacs and Sirts regulate numerous cellular and mitochondrial processes including gene transcription, DNA repair, protein stability, cytoskeletal dynamics, and signaling pathways to affect both development and aging. Of clinical relevance, Hdacs inhibitors are United States Food and Drug Administration-approved cancer therapeutics and are candidate therapies for other common diseases including arthritis, diabetes, epilepsy, heart disease, HIV infection, neurodegeneration, and numerous aging-related disorders. Hdacs and Sirts influence skeletal development, maintenance of mineral density and bone strength by affecting intramembranous and endochondral ossification, as well as bone resorption. With few exceptions, inhibition of Hdac or Sirt activity though either loss-of-function mutations or prolonged chemical inhibition has negative and/or toxic effects on skeletal development and bone mineral density. Specifically, Hdac/Sirt suppression causes abnormalities in physiological development such as craniofacial dimorphisms, short stature, and bone fragility that are associated with several human syndromes or diseases. In contrast, activation of Sirts may protect the skeleton from aging and immobilization-related bone loss. This knowledge may prolong healthspan and prevent adverse events caused by epigenetic therapies that are entering the clinical realm at an unprecedented rate. In this review, we summarize the general properties of Hdacs/Sirts and the research that has revealed their essential functions in bone forming cells (e.g., osteoblasts and chondrocytes) and bone resorbing osteoclasts. Finally, we offer predictions on future research in this area and the utility of this knowledge for orthopedic applications and bone tissue engineering.